RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $697

Benzinga · 3d ago
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $708 to $697.